Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

Citation data:

Journal of bone oncology, ISSN: 2212-1366, Vol: 7, Page: 1-12

Publication Year:
2017
Usage 85
Abstract Views 82
Link-outs 3
Captures 55
Readers 55
Mentions 5
News Mentions 5
Social Media 63
Shares, Likes & Comments 39
Tweets 24
Citations 2
Citation Indexes 2
PMID:
28413771
DOI:
10.1016/j.jbo.2017.03.001
Author(s):
Hadji, Peyman, Aapro, Matti S, Body, Jean-Jacques, Gnant, Michael, Brandi, Maria Luisa, Reginster, Jean Yves, Zillikens, M Carola, Glüer, Claus-C, de Villiers, Tobie, Baber, Rod, Roodman, G David, Cooper, Cyrus, Langdahl, Bente, Palacios, Santiago, Kanis, John, Al-Daghri, Nasser, Nogues, Xavier, Eriksen, Erik Fink, Kurth, Andreas, Rizzoli, Rene, Coleman, Robert E Show More Hide
Publisher(s):
Elsevier BV
Tags:
Medicine
Most Recent Tweet View All Tweets
Most Recent News Mention
review description
Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated bone loss (AIBL).

This review has 0 Wikipedia reference.